Literature DB >> 23728085

Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?

Po-Kuei Hsu1, Ling-I Chien, Chien-Sheng Huang, Chih-Cheng Hsieh, Yu-Chung Wu, Wen-Hu Hsu, Teh-Ying Chou.   

Abstract

OBJECTIVES: While neoadjuvant chemoradiation followed by surgery has been shown to improve the survival of patients with locally advanced oesophageal cancer, it is not known whether neoadjuvant chemoradiation has a beneficial or harmful effect on the non-responders. We aimed to compare the outcomes among neoadjuvant chemoradiation responders, non-responders and patients receiving primary oesophagectomies for resectable locally advanced oesophageal squamous cell carcinoma.
METHODS: Eighty-four non-T1-2N0 oesophageal squamous cell carcinoma patients were included. Thirty-eight patients received primary resection and 46 patients received neoadjuvant chemoradiation. The overall survival of chemoradiation responders (<50% residual tumour), non-responders (>50% residual tumour and those who shifted to definitive chemoradiation instead of surgery due to tumour progression) and patients receiving primary resection were compared. Clinical parameters were also compared between responders and non-responders.
RESULTS: There was no overall difference in survival between neoadjuvant chemoradiation and primary resection groups (2-year overall survival rates: 45.6 vs 54.3%, P = 0.442). In patients receiving neoadjuvant chemoradiation followed by surgery, pathological responders had significantly higher 2-year overall survival rates than non-responders (64.5 vs 38.9%, P = 0.043). While the pathological responders had the highest survival rate, clinicopathological non-responders (pathological non-responders and patients with tumour progression during the neoadjuvant chemoradiation period) demonstrated significantly worse outcomes than those receiving primary resection (32.0 vs 54.3%, P = 0.036). However, none of the clinical parameters, including blood profiles, images and baseline tumour characteristics, predicted the response to chemoradiation before treatment.
CONCLUSIONS: Neoadjuvant chemoradiation non-responders demonstrated no benefit and an even worse outcome compared with those receiving primary resection for locally advanced oesophageal squamous cell carcinoma. However, no significant clinical parameters could be implemented in the clinics to predict the response to neoadjuvant chemoradiation before treatment.

Entities:  

Keywords:  Neoadjuvant chemoradiation; Oesophageal cancer; Squamous cell carcinoma; Survival

Mesh:

Year:  2013        PMID: 23728085      PMCID: PMC3745136          DOI: 10.1093/icvts/ivt216

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  21 in total

1.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.

Authors:  S G Urba; M B Orringer; A Turrisi; M Iannettoni; A Forastiere; M Strawderman
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.

Authors:  Rajyalakshmi Luthra; Tsung-Teh Wu; Madan G Luthra; Julie Izzo; Enrique Lopez-Alvarez; Li Zhang; Jaime Bailey; Jeffrey H Lee; Robert Bresalier; Asif Rashid; Stephen G Swisher; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

3.  Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.

Authors:  Tsung-Teh Wu; Lucian R Chirieac; Susan C Abraham; Alyssa M Krasinskas; Huamin Wang; Asif Rashid; Arlene M Correa; Wayne L Hofstetter; Jaffer A Ajani; Stephen G Swisher
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

4.  Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.

Authors:  Rupert Langer; Katja Specht; Karen Becker; Philipp Ewald; Melitta Bekesch; Mario Sarbia; Raymonde Busch; Marcus Feith; Hubert J Stein; Jörg-Rüdiger Siewert; Heinz Höfler
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

5.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

6.  Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.

Authors:  Julie G Izzo; Usha Malhotra; Tsung-Teh Wu; Joe Ensor; Rajyalakshmi Luthra; Jeffrey H Lee; Stephen G Swisher; Zhongxing Liao; K S Clifford Chao; Walter N Hittelman; Bharat B Aggarwal; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

7.  Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?

Authors:  James M McLoughlin; Marcovalerio Melis; Erin M Siegel; E Michelle Dean; Jill M Weber; Jeannie Chern; Melanie Elliott; Scott T Kelley; Richard C Karl
Journal:  J Am Coll Surg       Date:  2008-05       Impact factor: 6.113

8.  Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.

Authors:  Min Kyoung Kim; Kyung-Ja Cho; Gui Young Kwon; Seung-Il Park; Yong Hee Kim; Jong Hoon Kim; Ho-Young Song; Ji Hoon Shin; Hwoon Yong Jung; Gin Hyug Lee; Kee Don Choi; Sung-Bae Kim
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

9.  Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; A M Correa; W L Hofstetter; D C Rice; M A Blum; A Suzuki; T Taketa; J Welsh; S H Lin; J H Lee; M S Bhutani; W A Ross; D M Maru; H A Macapinlac; J Erasmus; R Komaki; R J Mehran; A A Vaporciyan; S G Swisher
Journal:  Ann Oncol       Date:  2012-07-24       Impact factor: 32.976

10.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

View more
  9 in total

Review 1.  Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Hiroshi Saeki; Yuichiro Nakashima; Yoko Zaitsu; Yasuo Tsuda; Yuta Kasagi; Koji Ando; Yu Imamura; Kippei Ohgaki; Shuhei Ito; Yasue Kimura; Akinori Egashira; Eiji Oki; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2015-03-05       Impact factor: 2.549

Review 2.  Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer.

Authors:  Norihisa Uemura; Tadashi Kondo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 3.  State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Authors:  Jolinta Lin; Seth Kligerman; Rakhi Goel; Payam Sajedi; Mohan Suntharalingam; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 4.  Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.

Authors:  Baoxing Liu; Yacong Bo; Kunlun Wang; Yang Liu; Xiance Tang; Yan Zhao; Erjiang Zhao; Ling Yuan
Journal:  Oncotarget       Date:  2017-03-21

5.  PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.

Authors:  Nelson Adami Andreollo; Giovanni de Carvalho Beraldo; Iuri Pedreira Filardi Alves; Valdir Tercioti-Junior; José Antonio Possato Ferrer; João de Souza Coelho-Neto; Luiz Roberto Lopes
Journal:  Arq Bras Cir Dig       Date:  2018-12-06

6.  A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation.

Authors:  Yimin Li; Marcus Beck; Tom Päßler; Chen Lili; Wu Hua; Ha Dong Mai; Holger Amthauer; Matthias Biebl; Peter C Thuss-Patience; Jasmin Berger; Carmen Stromberger; Ingeborg Tinhofer; Jochen Kruppa; Volker Budach; Frank Hofheinz; Qin Lin; Sebastian Zschaeck
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

7.  Diffusion-weighted MRI and 18F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

Authors:  Xin Xu; Zhi-Yong Sun; Hua-Wei Wu; Chen-Peng Zhang; Bin Hu; Ling Rong; Hai-Yan Chen; Hua-Ying Xie; Yu-Ming Wang; Hai-Ping Lin; Yong-Rui Bai; Qing Ye; Xiu-Mei Ma
Journal:  Radiat Oncol       Date:  2021-07-19       Impact factor: 3.481

8.  The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  G W van Pelt; J A Krol; I M Lips; F P Peters; D van Klaveren; J J Boonstra; W O de Steur; R A E M Tollenaar; A Farina Sarasqueta; W E Mesker; M Slingerland
Journal:  Clin Transl Radiat Oncol       Date:  2019-11-27

9.  Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach.

Authors:  Yaowen Zhang; Jianpo Wang; Ningtao Dai; Peng Han; Jian Li; Jiangman Zhao; Weilan Yuan; Jiahuan Zhou; Fuyou Zhou
Journal:  BMC Cancer       Date:  2020-09-02       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.